NCT06751524 2024-12-30Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory ApprovalAgenus Inc.Available
NCT03554434 2020-03-02An Expanded Access Program for AM0010 (Pegilodecakin)Eli Lilly and CompanyNo longer available